Constraints on Star Forming Galaxies at z> 6.5 from HAWK-I Y-band Imaging of GOODS-South

We present the results of our search for high-redshift Lyman-break galaxies over the GOODS-South field. We use HST-ACS data in B, V, i' & z', VLT-ISAAC J and Ks, Spitzer-IRAC 3.6, 4.5, 5.8 and 8.0 micron data in conjunction with the new HAWK-I Y-band science verification data to search for dropout galaxies in the redshift range 6<z<9. We survey ~119 arcmin^2 to Y_AB=25.7 (5sigma), of which 37.5 arcmin^2 reaches Y_AB=25.9. Candidate z' and Y drop-outs were selected on the basis of a colour cut of (Y-J)_{AB}>0.75 mag and (z'-Y)_{AB}>1.0 mag respectively. We find no robust Y-drops (z~9) brighter than J_{AB}<25.4. In our search for z'-band dropouts (z~6.5-7.5), we identify four possible candidates, two with z'-drop colours and clear Spitzer-IRAC detections and two less likely candidates. We also identify two previously-known Galactic T-dwarf stellar contaminants with these colours, and two likely transient objects seen in the Y-band data. The implications if all or none of our candidates are real on the Ultra-Violet galaxy luminosity functions at z>6.5 are explored. We find our number of z'-drop candidates to be insufficient based on the expected number of z' drops in a simple no-evolution scenario from the z=3 Lyman-break galaxy luminosity function but we are consistent with the observed luminosity function at z~6 (if all our candidates are real). However, if one or both of our best z'-drop candidates are not z>6.5 galaxies, this would demand evolution of the luminosity function at early epochs. We show that the future surveys to be conducted with the ESO VISTA telescope over the next five years will be able to measure the bulk of the luminosity function for both z' and Y drop-outs.Comment: 14 pages, 15 figure. Accepted for publication in MNRA

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation

‘Tell me what you eat, and I will tell you who you are’: A Multi-Tissue and Multi-Scalar Isotopic Study of Diet and Mobility in Early Medieval England and its European Neighbours

This thesis is concerned with the impact of socio-economic, political and environmental shifts on Early Medieval communities, specifically England and its links with continental Europe. I have utilised multi-tissue (bone, dentine and enamel), multi-isotope (δ13C, δ15N, δ18O and 87/86Sr) and multi-proxy data to analyse the lifeways of people in Early Medieval England within a European context in a multi-scalar way (sub-continental, regional, kingdom and community scales). This meta-analytical approach has allowed me to investigate Early Medieval transitions across the first millennium AD and better characterise and disentangle human-environment interactions in the period. Throughout this thesis high levels of isotopic variability and cultural dynamism within Early Medieval communities are clear. The core themes of this work are – climate and environment, changing foodways and migration. This approach has allowed me to better provenance people based on isotopic diversity and see cross-cultural contact. It also highlights the impact of climate change (the Late Antique Little Ice Age and Medieval Warm Period) on human δ18O values, showing the widespread and relatively rapid impact these events had on climate and on drinking water sources. The significant diachronic changes in both diet and in mobility patterns found here reflect the highly dynamic and far from insular position of England within Europe in the first millennium AD. My analyses support a model of continual and relatively large-scale migration from the continent Europe across the period, and changes to foodways which reflect not just shifts in economics and agricultural practice but changing worldviews (e.g. the impacts of Christianisation). Isotopic data when combined with archaeo-historical evidence show that identity construction in Early Medieval communities was highly complex, and there is no clear link between isotopic patterns, genetics and grave goods usually seen as “ethnic” signifiers. I show that these were multi-origin communities in continual contact through long-distance networks which influenced the changes we see throughout the first millennium AD.Cambridge Trust, Newnham College, Leicestershire Archaeological and Historical Society, Kathleen Hughes Memorial Fund, Cambridge Philosophical Society and the University of Roehampton

"Monarchies and Monasteries" Christianisation and Centralisation Along Anglo-Saxon Waterways

This project aims to incorporate urban settlement data within a framework of landscape archaeology approaches to map the effects of Christianisation on town development in Anglo-Saxon England from the 7th-11th centuries A.D. With the introduction of Christianity to Anglo-Saxon England came churches, this coincided with increasing productivity and trade which necessitated the growth of towns and larger settlements. The great dynamism of this period both socially and economically has meant that previously studies have focused on single aspects of the changing Anglo-Saxon world, however this study aims to use multi-proxy evidence to demonstrate the need for more comparative and collaborative approaches. From the 7th century onward land ownership and estate management changed in England, shifting not long after the arrival of missionaries. There were also changes in elite sedentism, dynastic power shifts, and increasing settlement and economic centralisation. This project investigates the links between Christianisation and centralisation in Anglo-Saxon England. Links between placement of churches, town development, and changes in funerary behaviour are illuminated. One unifying factor in these settlements is waterways. The essential nature of these riverine and coastal landscapes highlights the multi-factorial nature of the Christianisation process from c. 600-1000 AD and beyond. The process of Christianisation is not a solely religious question, it affected most aspects of early medieval society, and lasted far longer than what has been historically accepted (c. 8th century A.D.). These questions of changing land ownership and settlement development are multi-faceted and intertwined

Multi-tissue and multi-isotope (δ13 C, δ15 N, δ18 O and 87/86 Sr) data for early medieval human and animal palaeoecology.

Human isotopic ecology at its core aims to study humans as a part of their environments, as animals within an ecosystem. We are complex animals with complicated foodways and mobility patterns that are hard to address without large multifaceted data sets. As biomolecular data from archaeological remains proliferates scientists are now at the stage where we are able to collate large bodies of data and undertake complex meta-analyses and address the complexities of human ecology and past socioenvironmental dynamics. Here we present a data set of 862 entries of new primary isotopic data (37 faunal bone, 235 human enamel carbonate with a subset of 18 for 87/86 Sr, 347 human bone, 243 human bulk dentine) within a larger data set compiled from available legacy data. It contains a total of 8,910 isotopic entries from ancient humans and animals relating to diet and mobility from the late Roman period into the Middle Ages (c. 400-1200 AD). It includes carbon, nitrogen, oxygen, and strontium isotope ratios from human bone, human dentine, faunal bone, and human bioapatite from thousands of individuals, and hundreds of sites found across 26 modern countries in western Europe. Studies have previously focused on only one of these aspects, compiling data sets for one tissue, or common isotopic pairing, or focusing on a particular site or region at a smaller scale for multi-isotope multitissue studies. This is the largest and first multitissue, multi-isotope, multiproxy data set of its kind from premodern populations. In publishing this data set, we hope to inspire more synthetic and meta-analytical work on human isotopic ecology. Insights from these data should lead to greater understanding of diet, agriculture, climate change, human-animal interactions, mobility/migration, and much more in the past. It is hoped that these insights into past socioenvironmental dynamics will help inform current discourse on human-environmental interactions. There are no copyright or proprietary restrictions on the data; these data papers should be cited when these data are used in publications. Additionally, we would like to hear from other researchers who use these data sets in teaching or for their own research.Cambridge Trust, Newnham College Cambridge, Cambridge Philosophical Society, Kathleen Hughes Memorial Fund, University of Roehampton, Leicestershire Archaeological and Historical Societ